Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 3/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23475913 | 0.87 | GLP1R (0.62) | GLP1RSIRT6SIRT1TLR2SIRT2 | |
| SCHEMBL18202629 | 0.87 | GLP1R (0.62) | GLP1RSIRT6SIRT1TLR2SIRT2 | |
| SCHEMBL27436033 | 0.87 | GLP1R (0.62) | GLP1RSIRT6SIRT1TLR2SIRT2 | |
| SCHEMBL23475930 | 0.87 | GLP1R (0.62) | GLP1RSIRT6SIRT1TLR2SIRT2 | |
| SCHEMBL27436089 | 0.85 | GLP1R (0.50) | GLP1RSIRT6SIRT1TLR2SIRT2 | |
| SCHEMBL26255822 | 0.84 | GLP1R (0.64) | GLP1RSIRT6SIRT1TLR2SIRT2 | |
| SCHEMBL16853273 | 0.84 | GLP1R (0.64) | GLP1RSIRT6SIRT1TLR2SIRT2 | |
| SCHEMBL23475938 | 0.82 | GLP1R (0.46) | GLP1RSIRT2MEN1KMT2A | |
| SCHEMBL23489665 | 0.82 | GLP1R (0.46) | GLP1RSIRT2MEN1KMT2A | |
| SCHEMBL26257014 | 0.81 | GLP1R (0.58) | GLP1RSIRT6SIRT1TLR2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | GLP1R 372/4885SIRT6 3192/4885SIRT1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.